Strategies for overcoming EGFR resistance in the treatment of advanced-stage NSCLC

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Somatic activating mutations in the epidermal growth factor receptor (EGFR) gene define a specific lung cancer subtype.
• EGFR mutations confer increased sensitivity to EGFR tyrosine kinase inhibitors (TKIs).
• First-generation (erlotinib, gefitinib) and second-generation (afatinib, dacomitinib) EGFR TKIs show significant efficacy in EGFR-mutant lung cancer.

Purpose of the Study:

• To review the clinical efficacy of EGFR TKIs in lung cancer patients with EGFR mutations.
• To discuss the inevitable development of acquired resistance to EGFR TKIs.
• To explore novel strategies for overcoming acquired resistance to EGFR TKIs.

Main Methods:

• Review of large phase III studies evaluating EGFR TKIs versus chemotherapy.
• Analysis of radiographic response rates and progression-free survival (PFS).
• Discussion of emerging therapeutic approaches for acquired resistance.

Main Results:

• EGFR-mutant lung cancer patients exhibit >60% radiographic response rates with EGFR TKIs.
• EGFR TKIs significantly improve PFS compared to chemotherapy in this cohort.
• Acquired resistance to EGFR TKIs is an inevitable clinical challenge.

Conclusions:

• Despite initial efficacy, acquired resistance limits long-term benefit from EGFR TKIs.
• Novel strategies including next-generation inhibitors, combination therapies, and chemotherapy are needed.
• Clinical trial enrollment for patients with acquired resistance is crucial for advancing treatment.